CTI BioPharma (NASDAQ:CTIC) and Celsion (NASDAQ:CLSN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.
Risk & Volatility
CTI BioPharma has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500. Comparatively, Celsion has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
This table compares CTI BioPharma and Celsion’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
63.4% of CTI BioPharma shares are held by institutional investors. Comparatively, 5.1% of Celsion shares are held by institutional investors. 2.7% of CTI BioPharma shares are held by insiders. Comparatively, 2.4% of Celsion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current recommendations for CTI BioPharma and Celsion, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CTI BioPharma presently has a consensus target price of $6.00, indicating a potential upside of 259.28%. Celsion has a consensus target price of $9.00, indicating a potential upside of 368.75%. Given Celsion’s higher possible upside, analysts clearly believe Celsion is more favorable than CTI BioPharma.
Valuation and Earnings
This table compares CTI BioPharma and Celsion’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CTI BioPharma||$25.15 million||3.85||-$40.67 million||($1.24)||-1.35|
Celsion has lower revenue, but higher earnings than CTI BioPharma. CTI BioPharma is trading at a lower price-to-earnings ratio than Celsion, indicating that it is currently the more affordable of the two stocks.
CTI BioPharma beats Celsion on 7 of the 13 factors compared between the two stocks.
CTI BioPharma Company Profile
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.